The toll-like receptors (TLR) are a family of protein that are responsible for pathogen recognition. TLR8 is expressed within the endolysosomal compartmental pathway and it is able to recognize the intracellular pathogens[3]. Motolimod is a novel small molecule TLR8 agonist with EC50 of about 100 nmol/L[4]. The THP-1 cells were treated with motolimod from 3 nM to 10 μM overnight. The IL-1β and IL-18 mRNA level measured by RT-PCR were significantly increased after the treatment of motolimod. The IL-β, caspase-1 and pro-IL-1 protein level were also increased significantly as detected by western blotting assay[5]. The hind paw of C57BL/6 mice was intradermally injected with 50 µg of motolimod and spontaneous pain behaviors were counted every 5 min for 30 min. It was found that the treatment of motolimod could induced lifting, flinching and licking in the first 15 min[6].
作用机制
Motolimod is an ultra-potent TLR8 selective agonist by binding with the TLR-8[7].
搜索
